Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study

BACKGROUND: Evogliptin (EVO) is a potent and selective dipeptidyl peptidase-4 inhibitor (DPP4i) developed for the treatment of type 2 diabetes mellitus (T2DM). DPP4is are known to exhibit a better glucose-lowering effect in Asians compared to other ethnic groups. Once EVO’s clinical development prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Cercato, Cintia, Felício, Joao Soares, Russo, Luis Augusto Tavares, Borges, Joao Lindolfo Cunha, Salles, Joao, Muskat, Patricia, Bonansea, Teresa, Chacra, Antonio Roberto, Eliaschewitz, Freddy Goldberg, Forti, Adriana Costa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923891/
https://www.ncbi.nlm.nih.gov/pubmed/31890041
http://dx.doi.org/10.1186/s13098-019-0505-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923891/
https://www.ncbi.nlm.nih.gov/pubmed/31890041
http://dx.doi.org/10.1186/s13098-019-0505-z

Ejemplares similares